Increased plasmatic soluble HLA-G levels in endometrial cancer

Yahia, Hamza Ben; Babay, Wafa; Bortolotti, Daria; Boujelbène, Nadia; Laaribi, Ahmed Baligh; Zidi, Nour; Kéhila, M; Chelbi, Hanène; Boudabous, Abdellatif; Mrad, Karima; Mézlini, Amel; Luca, Dario Di; Ouzari, Hadda‐Imene; Rizzo, Roberta; Zidi, Inès

doi:10.1016/j.molimm.2018.04.007

Cited by 23 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-classical HLA-G comprises four membrane-bound isoforms (HLA-G1 to HLA-G4) and three soluble isoforms (HLA-G5 to HLA-G7) ( 66 ). All HLA-G isoforms are detectable in the early and advanced stages of EC ( 67 ). The plasma levels of soluble HLA-G are significantly higher in patients with EC compared with that in healthy individuals.…”

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

“…The plasma levels of soluble HLA-G are significantly higher in patients with EC compared with that in healthy individuals. Additionally, soluble HLA-G5 molecules are more frequently observed than membrane-bound HLA-G1 molecules in patients with EC ( 67 ). Notably, the level of soluble HLA-G is higher in the early stages of EC compared with that in high-grade EC ( 67 ).…”

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

See 1 more Smart Citation

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

et al. 2020

View full text Add to dashboard Cite

Immunotherapy is an emerging clinical approach that has gained traction over the past decade as a novel treatment option for lung cancer and melanoma. Notably, researchers have made marked improvements in the treatment of endometrial cancer (EC), and potential immune responses have been identified in patients with EC, thereby offering the possibility of exploring immunotherapy for EC. Nevertheless, various needs remain unmet, and immunotherapy applications in EC have yielded limited success, as only a minority of patients exhibited a clinical response. Therefore, further understanding of immune dysfunction associated with EC is still required. The present review describes recent findings regarding the immunosuppressive microenvironment of EC, with emphasis on immune evasion mechanisms and immunotherapy in EC.

show abstract

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

Section: Immunosuppressive Microenvironment In Ecmentioning

confidence: 99%

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…They have observed a borderline relationship between sHLA‐G plasma levels and the grade of cancer, and patients with high‐grade cancers have expressed higher sHLA‐G levels than patients with low cancer grade ( P = 0.057). No statistically significant relation was identified between sHLA‐G and clinicopathological parameters . Barrier et al have examined the HLA‐G antigen in endometrial cancer patients.…”

Section: Discussionmentioning

confidence: 99%

The analysis of human leukocyte antigen‐G level in patients with endometrial cancer by Western blot technique

Walentowicz-Sadlecka

Dziobek

Grabiec

et al. 2018

American J Rep Immunol

View full text Add to dashboard Cite

The conditions that enable the cells of a primary tumour to initiate metastases to distant sites represent a crucial but still poorly understood clinical issue. Both tumour growth and the ability to initiate metastases are connected with the continuous interaction between cancer cells and their microenvironment, particularly with the immune system cells that surround the tumour nest. The human endometrium is where immune, endometrial, and fetal cell interactions are realized. The suppressive profile of the microenvironment within the endometrium constitutes the physiological phenomenon that allows for the proper implantation of the human ovum and the consequent development of pregnancy. Within the endometrium, the intensity of the selective suppression of immune cells is precisely controlled and limited to the moment of implantation that signals the

show abstract

“…HLA-Ib molecules also generate a pool of antibodies in vivo, which may include monospecific or polyreactive (cross-reactive with other HLA-I molecule [16,[35][36][37][38][39]. Soluble HLA-Ib is also found in the synovial fluid and the circulation of healthy and in cancer patients [40][41][42].…”

Section: Diagnostic and Clinical Relevance Of Non-classical Hla Class Ib Antigensmentioning

confidence: 99%

Monospecific and Polyreactive Monoclonal Antibodies against Human Leukocyte Antigen-E: Diagnostic and Therapeutic Relevance

Ravindranath¹,

Hilali²

2021

Monoclonal Antibodies

View full text Add to dashboard Cite

A monoclonal antibody (mAb) binds to an antigen recognizing an epitope (a sequence of amino acids). A protein antigen may carry amino acid sequence unique to that antigen as well as sequences found in other proteins. Human leukocyte antigens (HLA), a family of proteins expressed by the Major Histocompatibility Complex gene family represent a special case, in that it displays a high degree of polymorphism. Every HLA molecule possesses both specific (private) epitopes and epitopes shared (public) with other HLA class Ia and class Ib molecules. HLA-E is overexpressed in cancer cells more than any other HLA Class I molecules. Therefore specific localization of HLA-E with mAbs is pivotal for developing targeted therapy against cancer. However, the commercially available mAbs for immunodiagnosis are polyreactive. We have developed anti-HLA-E mAbs and distinguished monospecific from polyreactive mAbs using Luminex multiplex single antigen bead (SAB) assay. HLA-E-binding of monospecific-mAbs was also inhibited by E-restricted epitopes. The amino acid sequences in the region of the epitopes bind to CD94/NKG2A receptors on CD8+ T cells and NK cells and block their antitumor functions. Monospecific-HLA-E mAbs recognizing the epitopes sequences can interfere with the binding to restore the anti-tumor efficacy of NK cells. Also, monospecific-mAbs augment the proliferation of CD4-/CD+ cytotoxic T-lymphocytes. Therefore, anti-HLA-E monospecific-mAb can serve as a double-edged sword for eliminating tumor cells.

show abstract

Increased plasmatic soluble HLA-G levels in endometrial cancer

Cited by 23 publications

References 20 publications

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

The analysis of human leukocyte antigen‐G level in patients with endometrial cancer by Western blot technique

Monospecific and Polyreactive Monoclonal Antibodies against Human Leukocyte Antigen-E: Diagnostic and Therapeutic Relevance

Contact Info

Product

Resources

About